10272-49-8

Usage

Chemical Properties

mp 154-158°C

InChI:InChI=1/C11H15N.ClH/c1-2-4-10(5-3-1)11-6-8-12-9-7-11;/h1-5,11-12H,6-9H2;1H

Upstream product

• 43064-12-6 1,2,3,6-tetrahydro-4-phenylpyridine hydrochloride 
• 771-99-3 4-phenylpiperidine 
• 100-58-3 phenylmagnesium bromide 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 108-86-1 bromobenzene 
• 94163-98-1 1-benzyl-4-phenyl-1,2,5,6-tetrahydropirydine hydrochloride 
• 63843-83-4 1-benzyl-4-hydroxy-4-phenylpiperidine 
• 38025-45-5 1-benzyl-4-phenyl-1,2,3,6-tetrahydro-pyridine 

Downstream Products

• 774-52-7 1-methyl-4-phenylpiperidine 
• 98817-20-0 metilen-bis-<1,1'-(fenil-4)-piperidina> 
• 96402-15-2 7-Methyl-4-(4-phenyl-piperidin-1-ylmethyl)-3,4-dihydro-2H-benzo[b]oxepin-5-one 
• 110469-35-7 1-[6-Hydroxy-4-methoxy-7-(4-phenyl-piperidin-1-ylmethyl)-benzofuran-5-yl]-ethanone 
• 829-33-4 1-methyl-4-phenyl-piperidine; hydrochloride 
• 14827-76-0 5-[2-(4-phenyl-piperidin-1-yl)-ethyl]-oxazolidin-2-one 
• 26905-03-3 4-(4-Nitrophenyl)piperidine 
• 697304-21-5 ethyl (2R,3S)-3-(1H-indol-3-yl)-2-{[(4-phenylpiperidin-1-yl)carbonyl]amino}butanoate 
• 387827-41-0 2-[6-(4-phenyl-1-piperidinyl)hexyl]-1H-isoindole-1,3(2H)-dione 
• 691877-09-5 C₂₀H₂₅BrN₂O₂S 
• 374813-20-4 1-[(4-phenyl-1-piperidinyl)carbonyl]-1,2,3,4-tetrahydroquinoline 
• 400770-04-9 methyl 3-((4-phenyl)piperidin-1-yl)-1-isopropylcyclopentane carboxylate 
• 157133-89-6 2,2,2-trifluoro-1-(4-phenyl-1-piperidinyl)-1-ethanone 

Relevant academic research and scientific papers

Synthetic method of 4 -phenyl piperidine hydrochloride

The invention discloses a synthesis method of 4 -phenylpiperidine hydrochloride, and the route is as shown in the specification. The method has the advantages of cheap and easily available raw materials, simple operation and post-treatment, high yield, high product purity and the like, and is suitable for industrial production.

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6- tetrahydropyridines as 5-HT2C agonists

A series of substituted 4-arylpiperidines and a smaller family of 4-aryl-1,2,3,6-tetrahydropyridines were synthesized and their biological activity at the 5-HT2C receptor studied to determine whether either series showed noteworthy agonist activity. Structure-activity relationships were developed from the performed receptor binding assays and functional studies, and the results of the analysis are presented herein.

Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same

The invention concerns compounds corresponding to general formula (I), wherein, in particular: W represents hydrogen, COR6, CSR6, SO2R6, CO(CH2)nR6, (CH2)nR7; X represents CH or N; Y represents (CH2)n, CO, CH2CO, CH═CHCO, CH2CH2CO; Z represents a heterocycle. When Z=pyridine, then Y is other than CO. R1 represents hydrogen, C1-C6 alkyl, halogen OCH3, CF3; R2 and R3, identical or different, represent hydrogen, C1-C6 alkyl; R4 represents a) hydrogen, b) C1-C6 alkyl, c) an aryl, d) a heterocycle; R5 represents hydrogen, COR7R8, SO2R7, CO(CH2)nSR7, CO(CH2)nOR7, CONR7R8, CO(CH2)mCOR7; R6 represents a) a phenyl or a naphthyl, b) a C1-C6 alkyl, a cycloalkyl, c) a heterocycle, d) NR7R8; R7 and R8, identical or different, represent a) hydrogen, C1-C15 alkyl, b) a heterocycle, c) an aryl; n represents 0 to 10; m represents 2 to 10; provided that when Z represents a quinozaline or benzimidazole group, then R5 is other than CH2Ph or methyl and n is other than zero.

Phenoxyalkylamine derivatives useful as opioid receptor agonists

A medicament useful for preventive and/or therapeutic treatment of nerve system diseases which comprises, as an active ingredient, a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: wherein, X represents a group represented by the following general formula (II), (III), (IV), (V), or (VI), “A” represents a saturated or unsaturated 3- to 6-membered carbocyclic group and the like, “B” represents CH2 and the like, “n” represents 0 to 2, R1 represents a hydrogen atom, a halogen atom and the like, R2, R3, and R7 to R14 represent a hydrogen atom, a lower alkyl group which may be substituted and the like, R4 represents a hydrogen atom, a lower alkyl group which may be substituted and the like, R5 represents a hydrogen atom, a halogen atom and the like, R6 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, and R5 and R6, R7 and R8, R9 and R10, or R11 and R12 may bind to each other to form a cyclic structure.

Tetrahydrobenzindole compounds

A compound of formula (I) for use in the treatment or prevention of mental diseases A is N, CH, C having a double bond or CR5; each of B and Z is independently N, CH or CR1, with the proviso that A is N when B and/or Z is N; R1, R2, R3, R4and R5and n are as defined in the specification.

3-alkyl-3-phenyl-piperidines

PCT No. PCT/US97/15443 Sec. 371 Date Jan. 22, 1998 Sec. 102(e) Date Jan. 22, 1998 PCT Filed Sep. 2, 1997 PCT Pub. No. WO98/11090 PCT Pub. Date Mar. 19, 1998The small nonpeptides of the instant invention are tachykinin antagonists of formula or a pharmaceutically acceptable salt thereof wherein: R1 is straight or branched alkyl of from 5 to 15 carbon atoms, aryl, or heteroaryl; R2 is hydrogen, hydroxy, amino, or thiol; R3 is aryl, arylsulfonylmethyl, or saturated or unsaturated heterocycle; R4 is from 1 to 4 groups each independently selected from halogen, alkyl, hydroxy, and alkoxy; n is an integer of from 2 to 6; and the carbon atom of (CH2)n group can be replaced by oxygen, nitrogen, or sulphur. The compounds are highly selective and functional NK3 antagonists expected to be useful in the treatment of pain, depression, anxiety, panic, schizophrenia, neuralgia, addiction disorders, inflammatory diseases, gastrointestinal disorders, vascular disorders, and neuropathological disorders.

3-AMIDINOANILINE DERIVATIVES, ACTIVATED BLOOD COAGULATION FACTOR X INHIBITORS, AND INTERMEDIATES FOR PRODUCING BOTH

The present invention relates to a 3-amidinoaniline derivative represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group, a lower alkenyl group etc.; R1 represents a hydrogen atom, a hydroxy group, a lower alkyl group etc.; Y represents a single bond or an oxygen atom; and R2 represents a lower alkyl group or a group represented by the general formula: wherein n represents 1 or 2; and T represents a hydrogen atom or a group represented by the general formula:-C(=NH)-W wherein W represents a lower alkyl group; or a pharmaceutically acceptable salt thereof, which has a potent and selective activated blood coagulation factor X inhibitory activity, and an intermediate for producing both.

Combined analgesic/neuroleptic activity in N-butylrophenone prodine-like compounds

Some 4-phenyl-4-piperidinols, corresponding esters, and related compounds with a p-fluorobutyrophenone chain on nitrogen were synthesized and evaluated in in vitro and in vivo tests in order to examined their ability to interact contemporaneously with opioid and dopamine receptors. The propionyloxy derivatives showed a good combination of analgesic and neuroleptic activity. With a 3-methyl substituent on the piperidine ring, the β-configuration was the more active form not only for analgesic activity, as expected from previous results on prodines, but also for neuroleptic activity. Haloperidol and its propionate were also tested as reference compounds.